These results indicate that soluble DPP‐4 inhibits β‐adrenoreceptor‐stimulated UCP1 induction and that chronic DPP‐4 inhibitor treatment may prevent obesity through the activation of BAT function. The gene discussed is DPP4; the disease is obesity due to melanocortin 4 receptor deficiency.